IBM Watson Health and Illumina have officially joined forces, announcing a new partnership on Monday as the J.P. Morgan Healthcare Conference kicks off.
Watson Health is a serial collaborator, but it chose a pivotal agreement to spotlight at JPM. By integrating with Illumina’s platform, the two companies can create an end-to-end tumor sequencing workflow that could increase accessibility and scalability in the field. It could also address a major problem, said Watson Health Vice President Steve Harvey; a lack of standardization.
{iframe}http://medcitynews.com/2017/01/illumina-ibm-watson-form-cancer-genomics-partnership/?utm_source=hs_email&utm_medium=email&utm_content=40283986&_hsenc=p2ANqtz-8dz7gM7jtk71ut0XWQajveNLTGmumWQAVKmDx6wpHTJ8LdEXbAOEpbzL2PpdjGe0LLMh48OTKOu5iKxsP3pN0ZviBUQg&_hsmi=40283986{/iframe}